Shots: AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules Innate gains US and EU rights of Lumoxiti approved […]readmore
Tags : Existing Deal